Non-small-cell lung cancer: Role of the immune system and potential for immunotherapy

David P. Carbone, David R Gandara, Scott J. Antonia, Christoph Zielinski, Luis Paz-Ares

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

As the leading cause of cancer death worldwide, lung cancer continues to impose a major burden on healthcare systems and cause significant challenges for clinicians and patients. Most patients present with advanced disease at the time of diagnosis and have a poor prognosis, with the vast majority surviving less than 5 years. Although new therapies have been introduced in recent years that target molecular disease drivers present in a subset of patients, there is a significant need for treatments able to improve response and extend survival while minimizing effects on quality of life. Recent evidence of clinical efficacy for immunotherapeutic approaches for lung cancer suggests that they will become the next major therapeutic advance for this disease. Non-small-cell lung cancer, which accounts for approximately 85% of lung cancer cases, has historically been considered a nonimmunogenic disease; however, as with several other malignancies, recent data show that much of this lack of immune responsiveness is functional rather than structural (i.e., possible to overcome therapeutically). This review explores the key elements of the immune system involved in non-small-cell lung cancer and briefly examines immunotherapeutic strategies in development to shift the balance of immune activity away from a tumor-induced immune-suppressive state toward an active antitumor immune response.

Original languageEnglish (US)
Pages (from-to)974-984
Number of pages11
JournalJournal of Thoracic Oncology
Volume10
Issue number7
DOIs
StatePublished - Jul 4 2015

Fingerprint

Non-Small Cell Lung Carcinoma
Immunotherapy
Immune System
Lung Neoplasms
Active Immunity
Neoplasms
Cause of Death
Therapeutics
Quality of Life
Delivery of Health Care
Survival

Keywords

  • Cancer vaccines
  • Checkpoint inhibitors
  • Immune system
  • Immunotherapy
  • Non-small-cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Non-small-cell lung cancer : Role of the immune system and potential for immunotherapy. / Carbone, David P.; Gandara, David R; Antonia, Scott J.; Zielinski, Christoph; Paz-Ares, Luis.

In: Journal of Thoracic Oncology, Vol. 10, No. 7, 04.07.2015, p. 974-984.

Research output: Contribution to journalArticle

Carbone, David P. ; Gandara, David R ; Antonia, Scott J. ; Zielinski, Christoph ; Paz-Ares, Luis. / Non-small-cell lung cancer : Role of the immune system and potential for immunotherapy. In: Journal of Thoracic Oncology. 2015 ; Vol. 10, No. 7. pp. 974-984.
@article{d8896bd7ee7543a28489a3df2dac5c46,
title = "Non-small-cell lung cancer: Role of the immune system and potential for immunotherapy",
abstract = "As the leading cause of cancer death worldwide, lung cancer continues to impose a major burden on healthcare systems and cause significant challenges for clinicians and patients. Most patients present with advanced disease at the time of diagnosis and have a poor prognosis, with the vast majority surviving less than 5 years. Although new therapies have been introduced in recent years that target molecular disease drivers present in a subset of patients, there is a significant need for treatments able to improve response and extend survival while minimizing effects on quality of life. Recent evidence of clinical efficacy for immunotherapeutic approaches for lung cancer suggests that they will become the next major therapeutic advance for this disease. Non-small-cell lung cancer, which accounts for approximately 85{\%} of lung cancer cases, has historically been considered a nonimmunogenic disease; however, as with several other malignancies, recent data show that much of this lack of immune responsiveness is functional rather than structural (i.e., possible to overcome therapeutically). This review explores the key elements of the immune system involved in non-small-cell lung cancer and briefly examines immunotherapeutic strategies in development to shift the balance of immune activity away from a tumor-induced immune-suppressive state toward an active antitumor immune response.",
keywords = "Cancer vaccines, Checkpoint inhibitors, Immune system, Immunotherapy, Non-small-cell lung cancer",
author = "Carbone, {David P.} and Gandara, {David R} and Antonia, {Scott J.} and Christoph Zielinski and Luis Paz-Ares",
year = "2015",
month = "7",
day = "4",
doi = "10.1097/JTO.0000000000000551",
language = "English (US)",
volume = "10",
pages = "974--984",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "7",

}

TY - JOUR

T1 - Non-small-cell lung cancer

T2 - Role of the immune system and potential for immunotherapy

AU - Carbone, David P.

AU - Gandara, David R

AU - Antonia, Scott J.

AU - Zielinski, Christoph

AU - Paz-Ares, Luis

PY - 2015/7/4

Y1 - 2015/7/4

N2 - As the leading cause of cancer death worldwide, lung cancer continues to impose a major burden on healthcare systems and cause significant challenges for clinicians and patients. Most patients present with advanced disease at the time of diagnosis and have a poor prognosis, with the vast majority surviving less than 5 years. Although new therapies have been introduced in recent years that target molecular disease drivers present in a subset of patients, there is a significant need for treatments able to improve response and extend survival while minimizing effects on quality of life. Recent evidence of clinical efficacy for immunotherapeutic approaches for lung cancer suggests that they will become the next major therapeutic advance for this disease. Non-small-cell lung cancer, which accounts for approximately 85% of lung cancer cases, has historically been considered a nonimmunogenic disease; however, as with several other malignancies, recent data show that much of this lack of immune responsiveness is functional rather than structural (i.e., possible to overcome therapeutically). This review explores the key elements of the immune system involved in non-small-cell lung cancer and briefly examines immunotherapeutic strategies in development to shift the balance of immune activity away from a tumor-induced immune-suppressive state toward an active antitumor immune response.

AB - As the leading cause of cancer death worldwide, lung cancer continues to impose a major burden on healthcare systems and cause significant challenges for clinicians and patients. Most patients present with advanced disease at the time of diagnosis and have a poor prognosis, with the vast majority surviving less than 5 years. Although new therapies have been introduced in recent years that target molecular disease drivers present in a subset of patients, there is a significant need for treatments able to improve response and extend survival while minimizing effects on quality of life. Recent evidence of clinical efficacy for immunotherapeutic approaches for lung cancer suggests that they will become the next major therapeutic advance for this disease. Non-small-cell lung cancer, which accounts for approximately 85% of lung cancer cases, has historically been considered a nonimmunogenic disease; however, as with several other malignancies, recent data show that much of this lack of immune responsiveness is functional rather than structural (i.e., possible to overcome therapeutically). This review explores the key elements of the immune system involved in non-small-cell lung cancer and briefly examines immunotherapeutic strategies in development to shift the balance of immune activity away from a tumor-induced immune-suppressive state toward an active antitumor immune response.

KW - Cancer vaccines

KW - Checkpoint inhibitors

KW - Immune system

KW - Immunotherapy

KW - Non-small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84942902601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942902601&partnerID=8YFLogxK

U2 - 10.1097/JTO.0000000000000551

DO - 10.1097/JTO.0000000000000551

M3 - Article

C2 - 26134219

AN - SCOPUS:84942902601

VL - 10

SP - 974

EP - 984

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 7

ER -